IGMS Stock Overview
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.65 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$3.81 |
| Beta | 0.25 |
| 1 Month Change | -11.87% |
| 3 Month Change | -28.03% |
| 1 Year Change | -29.17% |
| 3 Year Change | -89.34% |
| 5 Year Change | n/a |
| Change since IPO | -68.52% |
Recent News & Updates
Recent updates
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20
We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Shareholder Returns
| IGMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | 0.4% | 1.0% |
| 1Y | -29.2% | 0.9% | 21.9% |
Return vs Industry: IGMS underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: IGMS underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| IGMS volatility | |
|---|---|
| IGMS Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IGMS's share price has been volatile over the past 3 months.
Volatility Over Time: IGMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 224 | Fred Schwarzer | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
| IGMS fundamental statistics | |
|---|---|
| Market cap | US$450.95m |
| Earnings (TTM) | -US$246.42m |
| Revenue (TTM) | US$2.13m |
211.7x
P/S Ratio-1.8x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGMS income statement (TTM) | |
|---|---|
| Revenue | US$2.13m |
| Cost of Revenue | US$213.79m |
| Gross Profit | -US$211.66m |
| Other Expenses | US$34.76m |
| Earnings | -US$246.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.18 |
| Gross Margin | -9,937.09% |
| Net Profit Margin | -11,568.83% |
| Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparison